Is Edrophonium considered peripherally active?

Edrophonium is primarily considered to be a peripherally active cholinergic agent. It functions as a reversible inhibitor of acetylcholinesterase, the enzyme responsible for breaking down acetylcholine. By inhibiting this enzyme, edrophonium increases the concentration of acetylcholine at synapses, particularly at the neuromuscular junctions. This enhancement of acetylcholine activity leads to improved transmission of nerve impulses to muscles, which is especially useful in the diagnosis of myasthenia gravis.

The "peripherally active" classification indicates that its primary effects are observed at the neuromuscular junction and not centrally within the brain. While edrophonium can cross the blood-brain barrier to some extent, its clinical applications and therapeutic effects predominantly occur outside the central nervous system, making it relevant for peripheral action. Thus, the characterization of edrophonium as peripherally active accurately reflects its primary mode of action and therapeutic relevance in enhancing neuromuscular transmission.